---
title: "FDA to Revisit Opioid Labeling for Chronic Pain"
date: 2025-07-11T16:01:36+08:00
categories: ["finance"]
tags: []
summary: "FDA Commissioner Dr. Marty Makary says the agency will revisit the labeling system for OxyContin and similar drugs, saying the original approval for chronic pain was “based on a 14-day study” and tain"
source_url: "https://www.bloomberg.com/news/videos/2025-07-11/fda-to-revisit-opioid-labeling-for-chronic-pain"
---

FDA Commissioner Dr. Marty Makary says the agency will revisit the labeling system for OxyContin and similar drugs, saying the original approval for chronic pain was “based on a 14-day study” and tainted by “regulatory capture.” He plans to ensure that a new system is consistent with the science. The action follows an April Bloomberg Businessweek investigation into how the agency’s labeling helped ignite the opioid crisis. (Source: Bloomberg)

---

*来源: [原文链接](https://www.bloomberg.com/news/videos/2025-07-11/fda-to-revisit-opioid-labeling-for-chronic-pain)*
